The ARHGEF28 Knockout A-549 Polyclonal Cells product comprises a population of CRISPR/Cas9-edited polyclonal knockout cells derived from the A-549 human lung carcinoma cell line, featuring targeted disruption of the ARHGEF28 gene. This polyclonal knockout format provides a heterogeneous pool of cells with engineered loss-of-function mutations in ARHGEF28, enabling robust assessment of gene function without clonal selection. The cells are suitable for studying Rho GTPase signaling and cytoskeletal regulation in a cancer-relevant background.
A-549 cells were originally isolated from the lung adenocarcinoma of a 58-year-old Caucasian male and serve as a widely used model of human alveolar type II epithelium. These adherent epithelial cells retain key characteristics of lung adenocarcinoma, including EGFR expression and integrin-mediated adhesion properties, making them particularly relevant for investigating molecular mechanisms underlying non-small cell lung cancer biology, tumor cell motility, and metastatic dissemination.
ARHGEF28 encodes a guanine nucleotide exchange factor that specifically activates Rho GTPases, predominantly RhoA, to orchestrate actin cytoskeleton reorganization, focal adhesion turnover, and cell migration. Upstream regulatory inputs include epidermal growth factor receptor (EGFR), Src kinase, and integrin signaling, while downstream effectors comprise RhoA, ROCK1/ROCK2, LIMK, and cofilin, culminating in stress fiber formation and actomyosin contractility. The protein interacts with focal adhesion components such as paxillin and focal adhesion kinase (FAK) as well as RND family GTPases, positioning ARHGEF28 at the nexus of growth factor and adhesion signaling pathways that govern cellular morphology and invasion.
In the A-549 lung carcinoma context, disruption of ARHGEF28 is expected to attenuate RhoA activation and consequently impair stress fiber assembly, focal adhesion maturation, and directed cell migration. This knockout model therefore recapitulates a loss-of-function scenario that can reveal the contribution of ARHGEF28-dependent RhoA signaling to the invasive phenotype of lung adenocarcinoma cells, providing a platform to dissect the molecular determinants of metastatic competence and to evaluate anti-metastatic therapeutic strategies targeting the cytoskeleton.
Researchers can employ this polyclonal knockout population in a range of functional experiments, including RhoA-GTP pull-down assays, phalloidin staining for actin stress fibers, Transwell migration and invasion chambers, wound healing assays, and immunofluorescence analyses of focal adhesion markers such as vinculin and phospho-FAK. These applications support investigations into Rho GTPase signaling, focal adhesion dynamics, and the mechanisms driving lung cancer metastasis. For more information or to request a quote, please contact Ascent Research.
